• Xeris Biopharma director John Johnson sold 15,000 common shares on June 4 at USD 6.09, cutting his stake to 683,083 shares.
• Johnson also received 24,193 common shares at no cost, lifting his holdings to 707,276 shares.
• He was granted stock options for 32,996 shares with an exercise price of USD 6.15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001410781-26-000004), on June 05, 2026, and is solely responsible for the information contained therein.